We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
A case of facial redness in atopic dermatitis occurring during dupilumab treatment successfully treated with topical delgocitinib ointment.
- Authors
Miyagaki, Tomomitsu; Okano, Tatsuro; Nakajima, Kaori; Mitsuishi, Shuhei; Kishi, Arisa; Miyano, Kaoru; Takeuchi, Sora; Kadono, Takafumi
- Abstract
After 2 weeks of dupilumab treatment, facial faint erythema disappeared (Figure 1B) and after 8 weeks his AD symptoms significantly improved. Dupilumab is a novel biologic targeted therapy directed to the interleukin (IL)-4 receptor alpha which has been approved for moderate-to-severe atopic dermatitis (AD) patients.
- Subjects
ATOPIC dermatitis; FACIAL care; ROSACEA; DRUG efficacy; JAPANESE people
- Publication
Dermatologic Therapy, 2021, Vol 34, Issue 2, p1
- ISSN
1396-0296
- Publication type
Article
- DOI
10.1111/dth.14888